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Abstract
Background. Bullous pemphigoid (BP) is the most common autoimmune bullous disease associated with 
higher mortality and coexisting comorbidities. The strongest relationship has been reported with neurologi-
cal diseases (NDs) but the particular type of ND differed depending on the study. There are some doubts 
on the prevalence of other comorbidities.
Objectives. The aim of this study was to compare the incidence of various comorbidities in a cohort of BP 
patients with controls.
Material and methods. A cohort of 218 patients (137 females, 81 males, aged 76.2 ±11.6 years) with newly 
diagnosed BP who were hospitalized at a specialized center in Poland in the years 2000–2014 was included 
in this retrospective study. The controls consisted of 168 sex- and age-matched individuals. Univariate and 
multivariate logistic regression analyses were performed to assess the association between the groups studied.
Results. At least 1 ND was present in 33.5% of BP patients vs 11.3% of controls. A strong association between 
the incidence of NDs and BP was found (OR = 3.76; 95% CI = 2.13–6.65; p < 0.001), especially for dementia 
(20.6% vs 2.9%, OR = 7.89; 95% CI = 2.99–20.85; p < 0.001). Surprisingly, BP patients with ND were 
older than the BP patients without ND (79.2 vs 74.7 years), and similarly for dementia (81.08 vs 74.90 years). 
The same was observed in comparison with controls. Arterial hypertension, among other comorbidities, was 
a strong independent factor associated with BP (OR = 2.17; 95% CI = 1.35–3.49; p < 0.001). Malignancies 
were observed more frequently in BP patients than in controls (12.8% vs 9%) but such association was 
significant in univariate analysis only.
Conclusions. Neurological diseases, particularly dementia, had a significant association with BP. A strong 
relationship with arterial hypertension and weak relationship with malignancies were noted. Thus, for ap-
propriate medical care, patients with BP need accurate screening for dementia and control of comorbidities 
with interdisciplinary management.
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Introduction
Bullous pemphigoid (BP) is  the most common auto-
immune bullous disorder caused by autoantibodies di-
rected against BPA2 (BP180) and BPA1 (BP230) proteins 
located in the basement membrane zone (BMZ). Clinically 
it is characterized by tense bullae, urticarial skin lesions 
and pruritus, primarily affecting elderly individuals, with 
risk increasing with age.1,2 The worldwide incidence ranges 
from 6.6 to 42.8 new cases per million people yearly while 
in Poland the BP incidence is estimated at 7 per million in-
habitants per year. Bullous pemphigoid is a potentially fatal 
disease with 1-year and 3-year mortality rates assessed 
at 22.4% and 39.5%, respectively, in Polish BP patients.3,4
In recent years, many epidemiological studies have in-
vestigated the coexistence of BP with various comorbidi-
ties. In fact, the most intense research has been focused 
on neurological diseases (NDs), showing that BP patients 
are more likely to  have any type of  ND.2,5–7 However, 
the particular types of ND among BP patients differed 
depending on the study and some results were even con-
flicting.1,2,5,6,8–13 Some data found a  higher prevalence 
of stroke, dementia, Parkinson’s disease, epilepsy, and mul-
tiple sclerosis in BP.1,2,5,6,8–14 Other studies have also identi-
fied psychiatric diseases such as schizophrenia, personality 
or unipolar/bipolar disorders as a risk factor for BP.6,15 
Moreover, some studies have referred to the  incidence 
of malignancies in BP patients, with some showing a higher 
proportion in BP patients.16–19 In spite of this, the debate 
is ongoing and this relationship remains controversial. 
There are several publications in the literature that have 
reported a higher prevalence of arterial hypertension in BP 
patients. The fact is that this disease may play an impor-
tant role in BP patients, especially since major drugs used 
to treat hypertension such as diuretics, ACE inhibitors 
or spironolactone can provoke BP.6,13,20–22 Among other 
comorbidities, single studies have demonstrated the as-
sociation of BP with diabetes.23–25
To confirm or reject the abovementioned discrepan-
cies, the aim of this study was to assess the relationship 
between BP and selected comorbidities. The groups of NDs 
(dementia, stroke, Parkinson’s disease, epilepsy, multiple 
sclerosis, and depression), cardiovascular diseases (arterial 
hypertension, arrhythmia, coronary artery disease, heart 
failure, and thromboembolic syndrome), malignancies, 
and diabetes mellitus were included.
Material and methods
The patients were diagnosed and treated in the Depart-
ment of Dermatology and Immunodermatology at the Medi-
cal University of Warsaw (Poland) in the period 2000–2014. 
The retrospectively-assessed group consisted of 386 persons 
(218 BP patients and 168 controls). The BP diagnosis was based 
on clinical features and positive direct immunofluorescence 
(DIF) of perilesional skin (linear IgG and/or C3 deposits along 
the BMZ). Additionally, indirect immunoﬂuorescence (IIF) 
detecting circulating anti-BMZ antibodies and/or examina-
tion of salt split skin and/or enzyme-linked immunosorbent 
assay (ELISA) for anti-BP180 NC16a (MESACUP BP 180 
ELISA kit; Medical&Biological Laboratories, Nagoya, Japan) 
were performed. In the group studied, almost all BP patients 
were positive for circulating autoantibodies (in 95.7%).
The controls were randomly selected from patients ad-
mitted in  the same period due to other dermatological 
diseases such as eczema, drug eruptions, erysipelas, her-
pes zoster, leg ulcers, urticaria, atopic dermatitis, scabies, 
erythema multiforme, lichen planus, or pityriasis rubra 
pilaris. Subjects with dermatological diseases character-
ized by systemic symptoms (e.g., connective tissue disor-
ders, psoriasis, lymphoma) were not included to the control 
group. The diagnosis of particular additional diseases was 
based on a reliable anamnesis or medical documentation 
including the results of appropriate tests. If any uncertainty 
was present, a cardiologist and/or a neurologist was asked 
for a medical consultation to confirm or reject a diagnosis.
Approval from the local Ethics Committee of the Medi-
cal University of Warsaw was obtained before starting 
the study.
Statistical analysis
The patients with BP and controls were compared us-
ing either the Student’s t-test or  the Wilcoxon test ac-
cording to the parameters of distribution assessed with 
the Kolmogorov-Smirnov test. Variables with a normal 
distribution are presented as a mean followed by standard 
deviation (SD). Variables not showing the normal distri-
bution are presented as a median with range values. For 
categorical variables, the differences between groups were 
compared using the exact Fisher test. All tests were double-
sided. Correlations were evaluated using Spearman correla-
tion coefficients. Crude and adjusted odds ratios (OR) and 
a 95% conﬁdence interval (95% CI) were estimated using 
univariate and multivariate logistic regression analyses for 
both groups. An association model was constructed using 
BP diagnosis as the dependent variable. Values of p < 0.05 
were considered statistically significant. Analyses were per-
formed using a statistical software package (STATISTICA 
v. 12; StatSoft Inc., Tulsa, USA).
Results
Among the cohort of 218 BP patients, 137 (62.8%) were fe-
male and 81 (37.2%) were male. In the 168 controls there were 
101 (60.1%) females and 67 (39.9%) males. Mean age at BP 
diagnosis was 76.2 ±11.62 years, median 78 years (range: 33–
100 years); and mean age for the controls was 75 ±10.92 years, 
median 77 years (range: 33–92 years). The BP patients and 
controls were age- and gender-matched (Table 1).
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Neurological diseases
At least 1 ND was found in 73 BP patients (33.5%) and 
in 19 controls (11.3%). The significant association between 
BP and the incidence of NDs was confirmed in multivari-
ate regression analysis (OR = 3.76, 95% CI = 2.13–6.65, 
p < 0.001) (Table 1). Thirteen BP patients (6%) had 2 NDs 
in comparison with none in the controls. The mean age 
of BP patients with ND was 79.2 vs 74.7 years in patients 
without ND. The same was observed in comparison with 
controls (Table 2). The most frequent ND in BP was de-
mentia, which was observed in 45 (20.6%) patients, followed 
by stroke in 28 (12.8%), Parkinson’s disease in 11 (5%), epi-
lepsy in 1 patient, and multiple sclerosis in 1 other patient. 
In the controls, stroke was the most frequently observed ND 
in 9 (5.3%) subjects, followed by dementia in 5 (2.9%), Parkin-
son’s disease in 3 (1.7%), epilepsy in 1, and multiple sclerosis 
in 1 individual. The BP patients had a significantly increased 
risk for dementia (OR = 8.48, 95% CI = 3.27–21.90, p < 0.001) 
and stroke (OR = 2.60, 95% CI = 1.19–5.69, p = 0.01) assessed 
by univariate analysis, whereas only dementia remained 
statistically significant in multivariate regression analy-
sis (OR = 7.89, 95% CI = 2.99–20.85, p < 0.001) (Table 1). 
A statistically higher age for BP patients with dementia vs 
without was observed (81.1 vs 74.97 years, p = 0.001) (Fig. 1).
Table 1. Univariate and multivariate regression analysis of comorbidities influencing bullous pemphigoid and controls 
 Variable BP patients n = 218 [%]
Controls 
n = 168 [%] p-value
Univariate analysis 
in BP patients Multivariate analysis in BP patients
aOR (95% CI) p-value bOR (95% CI) p-value cOR (95% CI) p-value
Gender: female 137 (62.8) 101 (60.1) 0.60 – – – – – –
Age [years] 76.23 ±11.62 75.03 ±10.92 0.30 – – – – – –
Any neurological 
disease 
73 (33.5) 19 (11.3) <0.001 3.95 (2.26–6.89) <0.001 3.67 (2.05–6.55) <0.001 3.76 (2.13–6.65) <0.001
Dementia 45 (20.6) 5 (2.9) <0.001 8.48 (3.27–21.9) <0.001 7.86 (2.94–21.03) <0.001 7.89 (2.99–20.85) <0.001
Stroke 28 (12.8) 9 (5.3) 0.01 2.60 (1.19–5.69) 0.01 2.12 (0.91–4.94) 0.08 2.18 (0.95–4.98) 0.06
Parkinson’s disease 11 (5) 3 (1.7) 0.1 2.92 (0.80–10.69) 0.1 3.03 (0.74–12.32) 0.11 – –
Multiple sclerosis 1 (0.5) 1 (0.6) 1.0 0.77 (0.04–12.50) 0.85 1.05 (0.06–17.92) 0.97 – –
Epilepsy 1 (0.5) 1 (0.6) 1.0 0.77 (0.04–12.50) 0.85 0.86 (0.05–14.46) 0.91 – –
Arterial hypertension 166 (76.1) 100 (59.2) <0.001 2.17 (1.40–3.37) <0.001 2.16 (1.31–3.73) 0.002 2.17 (1.35–3.49) 0.001 
Stable coronary artery 
disease
82 (37.6) 48 (28.5) 0.06 1.51 (0.98–2.33) 0.06 1.29 (0.77–2.15) 0.32 – –
Myocardial infarction 16 (7.3) 12 (7.1) 1.0 1.03 (0.47–2.23) 0.94 0.84 (0.34–2.08) 0.71 – –
Thromboembolic 
events
13 (5.9) 4 (2.3) 0.13 2.6 (0.83–8.15) 0.1 2.51 (0.71–8.80) 0.14 – –
Arrhythmias 46 (21.1) 26 (15.4) 0.18 1.46 (0.86–2.48) 0.16 1.40 (0.79–2.50) 0.24 – –
Malignancies 32 (14.6) 13 (7.7) 0.03 2.05 (1.03–4.60) 0.03 1.74 (0.84–3.65) 0.13 1.92 (0.94–3.96) 0.07
Diabetes mellitus 47 (21.5) 33 (19.6) 0.70 0.64 (0.68–1.85) 0.64 0.97 (0.54–1.72) 0.91 – –
 acrude OR (95% CI), badjusted OR (95% CI) to age and gender, analyzed to all variables, cadjusted OR (95% CI) analyzed to significant values; BP – bullous 
pemphigoid; OR – odds ratio.
Fig. 1. Age of bullous pemphigoid (BP) patients and controls with and 
without dementia
Table 2. Age of BP patients and controls with and without selected 
comorbidities
Variable
Age
p-value
BP patients controls
Neurological disease
yes 
no
79.21 ±7.50
74.73 ±12.99
76.15 ±9.85
74.89 ±11.07
0.14
0.91
Dementia
yes
no
81.08 ±7.32
74.97 ±12.21
73.80 ±16.42
75.07 ±10.78
0.07
0.93
Stroke
yes
no
77.67 ±7.89
76.02 ±12.08
74.77 ±7.89
75.05 ±11.08
0.34
0.44
Arterial hypertension
yes
no
78.00 ±10.22
70.59 ±13.95
75.88 ±10.08
73.79 ±12.01
0.10
0.18
Malignancies
yes
no
77.81 ±9.87
75.96 ±11.90
72.15 ±10.88
75.27 ±10.92
0.09
0.58
82
81
80
79
78
77
76
75
74
73
72
71
82
81
80
79
78
77
76
75
74
73
72
71
BP patients with dementia (n = 45, 81.09 ±7.32 years)
BP patients without dementia (n = 173, 74.97 ±12.20 years)
controls with dementia (n = 5, 73.30 ±16.42 years)
controls without dementia (n = 163, 73.07 ±10.73 years)
p = 0.80p = 0.0015
age of BP patients with  
and without dementia
age of controls with  
and without dementia
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Malignancies
A history of malignancies was recognized in 32 BP pa-
tients (14.6%) and 13 controls (7.7%). This relationship with 
malignancy occurrence in BP was statistically significant 
for univariate analysis only (OR = 2.05, 95% CI = 1.03–4.60, 
p = 0.03). The BP patients and controls had a history of simi-
lar types of cancers, and the most common ones in BP pa-
tients and controls were also the most common in the gen-
eral population (such as lung, prostate, breast, ovarian, and 
colon cancers as well as lymphoma or leukemia).
Other comorbidities
Out of all examined comorbidities, at least 1 comorbidity 
was present in 199/218 (91.3%) of BP patients and in 132/168 
(78.6%) of controls. In BP patients and controls, arterial 
hypertension was the most frequent comorbidity (in 76.1% 
and 59.2% subjects, respectively). Arterial hypertension was 
independently associated with BP in multivariate regres-
sion analysis (OR = 2.17, 95% CI = 1.35–3.49, p = 0.001). 
No association with diabetes mellitus among patients and 
controls was found. Chronic various drug intake was noted 
in 96% of BP patients. The most frequently prescribed drugs 
in BP were ACE-inhibitors, furosemide, calcium channel 
blockers, aspirin, proton pump inhibitors, and statins.
Discussion
Association with neurological diseases
Our case-control study has shown a remarkably higher 
incidence of NDs in BP patients (33.5% vs 11.3% in controls). 
This is consistent with other studies published so far, where 
ND rates ranged from 23% to 73.8% in BP patients and from 
4% to 24.2% in controls.2,5,7–14,23,26,27  Additionally, our re-
sults have indicated that Polish BP patients were approx. 
4 times more likely to suffer from any type of ND as com-
pared to other individuals. This high value is also comparable 
with the results of a recently-published first meta-analysis 
covering 14 case-control or population-based studies from 
Europe (Czech Republic, France, Italy, Portugal, Denmark, 
Spain, and the UK), the US and Asia (Taiwan and Malaysia).14 
In this meta-analysis, BP patients have been estimated to be 
5 times more likely to have ND than the general population.14
Moreover, similarly to  previously published studies, 
we were not able to demonstrate that all NDs assessed 
separately had a higher association with BP. The reasons 
for these discrepancies between various studies may be 
explained by  the different age of BP patients, relatively 
small patient groups in some evaluations, different selec-
tion of control groups, environmental factors, and finally, 
low morbidity for certain NDs such as epilepsy or multiple 
sclerosis. Also, the retrospective nature of the studies dis-
cussed may have influenced these differences.
In fact, we have shown that dementia was the only ND 
significantly associated with BP as demonstrated using mul-
tivariate regression analysis. Occurring in 20.6%, dementia 
in our BP patients remained in the middle range of per-
centages in comparison to previously published studies, 
where the frequency oscillated from 5.3% to 42.7%.1,2,5,6,8–
13,26,27 It is also important to note that, based on data from 
PubMed, dementia was independently associated with BP 
in all of the 13 case-control or population-based studies 
evaluating the relationship of this entity among BP patients 
confirmed by multivariate regression analysis, although 
the incidence of dementia varied considerably and ranged 
from 2.5 to 12.9 times more than in the general popula-
tion.1,2,5,6,9–12,14 Our BP patients faced a 7.86-fold increased 
risk of dementia, similarly to English patients with BP.5
Surprisingly, we observed a much older age of BP patients 
with dementia compared to BP patients without this condi-
tion (a difference of 8 years, p = 0.0015). The same was true 
when compared to the control group (a difference of 8 years, 
p = 0.07). In the  literature, the data on BP patients’ age 
with dementia is very limited. Only Langan et al., in a large 
group of 868 patients and 3,453 controls, noted a higher 
proportion of elderly BP patients with dementia compared 
to healthy controls with dementia.1
Interestingly, similarly to dementia, our BP patients with 
any type of ND were also older than BP patients without 
ND (a difference of 5 years). In the literature, several stud-
ies have evaluated the mean age of BP patients with any 
type of ND, showing that French, German and Iranian 
populations of BP patients with ND were much older than 
those without ND (a difference of 4, 7 and 17 years, respec-
tively).7,11,28 The significance of the abovementioned find-
ings is difficult to explain, especially as one could expect 
the opposite results. It seems that these unexpected results 
need confirmation in subsequent observations.
In our BP patients, the profile of other NDs was 12.8% for 
stroke, 5% for Parkinson’s disease, less than 1% for epilepsy, 
and less than 1% for multiple sclerosis, being the closest 
to the French group of BP patients.8  According to the litera-
ture, the prevalence of stroke in BP is estimated at between 
7.7% to 44.4%, Parkinson’s disease is reported between 2.3% 
and 17.9% of BP patients, the frequency of epilepsy varies 
from 2% to 11.1% and the frequency of multiple sclerosis 
is estimated at between 0% and 5%.1,2,5,6,8–11,13–15,26–28
We identified a relationship between BP and stroke, but 
the association was lost in the multivariate regression analy-
sis. In fact, 12 case-control or population-based studies out 
of 15 which evaluated the prevalence of stoke in BP using 
multivariate regression analysis showed no significant asso-
ciation of this disorder among BP patients.1,2,5,6,8–11,13–15,26,27
Our study did not show greater incidences of multiple 
sclerosis, Parkinson’s disease or epilepsy among BP patients 
either. Although the relationship between multiple scle-
rosis and BP is the strongest among all the NDs, probably 
due to the autoimmune nature of both disorders, studies 
of American and Iranian populations of BP patients did not 
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show an increased risk of multiple sclerosis, similarly to our 
study.2,11 Congruous observations for Parkinson’s disease 
or epilepsy and BP can be noted too. Until now, in 4 case-
control studies, an increased relationship with Parkinson’s 
disease was revealed1,2,6,10,12 but the results of 5 others did 
not confirm this observation with multivariate regression 
analysis.2,5,10,13 Likewise, several studies have investigated 
the prevalence of epilepsy in BP and in 3 of them a positive as-
sociation was observed,1,10,15 while the English, Malaysian and 
Iranian studies did not note such an association at all.5,11,13
The interaction between NDs and BP might play a crucial 
role in the explanation of the pathological mechanisms 
in BP. In fact, both cutaneous BP antigens BPA2 and BPA1 
(neuronal isoform) are found in the central nervous system. 
It has been suggested that alterations of the blood–brain 
barrier in the course of NDs may expose the neuronal BP 
antigens leading to an autoimmune response which results 
in the development of BP. A recent study by Messingham 
et al. proved that patients with various forms of dementia 
and Parkinson’s disease even without BP had BPA2 anti-
bodies detected in 23% and 37% of cases, which may con-
firm this hypothesis.29 Such patients have been suggested 
to represent a pre-disease state in which, firstly, neuronal 
immunoreactivity against BP180 is manifested, and later, 
as a result of some additional triggers, cutaneous autoim-
munity is developed.30
Association with malignancies
In contrast to NDs, the relationship between BP and ma-
lignancies has been under debate for many years. The re-
sults of our study showed a positive association between 
BP and malignancy occurrence, but various case-control 
studies have revealed the opposite results so far. Based 
on data from studies published in PubMed, the incidence 
of  malignancies among BP patients ranged from 5.8% 
to even 21.3%. However, in some of these studies, no as-
sociation was observed as compared to the control group. 
For example, a large English epidemiological study which 
included many cases of BP patients did not detect a higher 
risk of cancer in these patients in contrast to the general 
population.16 In another study carried out by Lindelof et al. 
in Swedish BP patients, no association between BP and ma-
lignancies was found.31 Unlike the abovementioned stud-
ies, some others have suggested an increased frequency 
of malignancies in BP patients.17,18,19,23 Studying a German 
population of BP patients (1,743 patients), Schulze et al. 
found that BP patients face a 2.5-fold higher risk of differ-
ent hematological malignancies, with a percentage of 6.7% 
in BP patients.19 Moreover, Ogawa et al. investigated a large 
Japanese population of BP patients (1,113 patients) and 
found malignant diseases in 5.8% of patients compared 
with 0.61% among controls.18 In addition, a case-control 
study of the Danish population disclosed a slightly higher 
incidence of tumors in BP patients (14%), but no statistical 
analysis was conducted to clarify these findings.23 There 
are also numerous single case reports that have determined 
the co-existence of certain carcinomas. These cases were 
analyzed jointly by Balestri et al., showing that cancers 
of the prostate, breast, stomach and colon, as well as lym-
phoma and leukemia were observed the most often in BP 
patients.32
Some authors have emphasized that the coexistence of BP 
and malignancies should not be found surprising as they 
result from the high rate of malignancies in this elderly 
patient population. The open question is if there is a com-
mon pathophysiological pathway of BP and malignancies. 
So far, several hypotheses have been proposed to explain 
this concomitance. The first and main theory suggests that 
antibodies against tumor-specific antigens may cross-react 
with the BMZ. Another one indicates that a tumor could 
secrete a hormone-like substance destroying BMZ, which 
causes the production of anti-BP antibodies. Another hy-
pothesis considers the role of an external factor, e.g., a virus, 
which could be tumorigenic and lead to BMZ destruction 
at the same time.32
Association with cardiovascular diseases
Finally, our data demonstrated the significant association 
between BP and arterial hypertension revealed by multi-
variate regression analysis. The prevalence of hypertension 
appears to be around 30–45% of the general population, 
with a steep increase with ageing.33 In both groups studied, 
arterial hypertension was the most common comorbidity, 
however it seems to be more frequent in BP patients. Our re-
sults were consistent with recently published studies carried 
out by Kremer et al., who found that arterial hypertension 
was the most frequent comorbidity in BP (in 64% of patients 
studied, p = 0.04).21 In studies by Kwan et al. and Cai et al., 
arterial hypertension was also the most frequent out of all 
comorbidities (in 62.8% and 59.3%, respectively).13,20 In an-
other study concerning BP patients, multi-morbidity was 
observed in 84% with the highest percentage for arterial 
hypertension.22 On the other hand, Jedlickova et al. did not 
find differences in cardiovascular disease incidences among 
patients with BP and controls.7
Nevertheless, a certain role in the pathogenesis of BP 
is attributed to drug consumption, especially agents used 
to treat hypertension. We suppose that positive association 
with arterial hypertension occurrence in our patients might 
also be related to antihypertensive drugs, which in some 
cases could certainly contribute to inducing or exacerbat-
ing BP.23 Similarly, in our BP patients with arterial hyper-
tension, the intake of at least 1 antihypertensive drug was 
noted; therefore, the potential influence of prescribed treat-
ment on BP course cannot be excluded either.
Limitations
Our single-center study includes some limitations. 
The first is  the retrospective nature of our evaluation. 
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Moreover, the hospitalized patients with other dermato-
logical conditions serving as controls in this study might 
contribute to a certain selection bias.
Conclusions
Our study on a relatively large group of BP patients dem-
onstrated a significantly higher prevalence of various NDs, 
especially dementia. Surprisingly, the BP patients with any 
NDs, presented were older than the BP subjects without 
these disorders. Among other common comorbidities, 
arterial hypertension and other malignancies typical for 
the general population were the ones most associated with 
BP occurrence. For appropriate medical care, patients with 
BP need accurate screening, especially for dementia and 
any neurological abnormalities. Interdisciplinary manage-
ment of BP patients including dermatologists, neurologists, 
cardiologists, and general practitioners is strongly required.
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